Clinical trials: Terminal Illness
Terminal Illness, End-of-Life Care
Non-Invasive Detection and Preservation of Neurocognitive Signals in the Peri-Death Period Using Brain-Computer Interface and Artificial Intelligence
Background: Recent electroencephalography (EEG) data indicate that the transition from clinical death to cellular death is marked by highly organized neurophysiological events, including significant surges in gamma-band power…
- Conditions
- Terminal Illness, End-of-Life Care, Death, Brain Death
- Trial name
- NeuroCogPresv (NCT07477028)
- Volunteers
- 20 people
- Sponsor
- Noah Tech, Corp.
Terminal Illness
Open-Label Treatment Extension of Protocol MNTX 301
This study is an open-label extension allowing patients who have completed Protocol MNTX 301 to continue to receive SC MNTX.
- Trial name
- NCT01367600
- Testing
- SC Methylnaltrexone (MNTX)
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Bausch Health Americas, Inc.
Terminal Illness
Open-Label Treatment Extension of Protocol MNTX 302
This is a 3 month open-label extension study that allows patients who completed Protocol MNTX 302 to receive SC MNTX.
- Trial name
- NCT01367613
- Testing
- SC Methylnaltrexone
- Where
- United States
- Volunteers
- 89 people
- Sponsor
- Bausch Health Americas, Inc.